Prognostic utility of cell cycle progession score in men with prostate cancer after primary external beam radiation therapy: In regard to Freedland et al

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 1, 2014, Pages 237-240

  Berlin, Alejandro ^a   Sykes, Jenna ^a   Dal Pra, Alan ^a   Catton, Charles ^a   Van Der Kwast, Theodorus ^b   Bristow, Robert G ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA C; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53;

ANDROGEN DEPRIVATION THERAPY; CAG REPEAT; CELL CYCLE; CELL CYCLE PROGESSION SCORE; COMPARATIVE GENOMIC HYBRIDIZATION; EXTERNAL BEAM RADIOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NOTE; OVERALL SURVIVAL; PLOIDY; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84890488861     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.10.009     Document Type: Letter

References (25)

1. S.J. Freedland, L. Gerber, and J. Reid Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy Int J Radiat Oncol Biol Phys 86 2013 848 853
2. J. Cuzick, G.P. Swanson, and G. Fisher Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: A retrospective study Lancet Oncology 12 2011 245 255
3. J.J. Cuzick, D.M.D. Berney, and G.G. Fisher Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer 106 2012 1095 1099
4. M.R. Cooperberg, J.P. Simko, and J.E. Cowan Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort J Clin Oncol 31 2013 1428 1434
5. A.A. Pollack, D.J.D. Grignon, and K.H.K. Heydon Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: An analysis of RTOG 8610 J Clin Oncol 21 2003 1238 1248
6. G. Fisher, Z.H. Yang, and S. Kudahetti Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort Br J Cancer 108 2013 271 277
7. M. Milosevic, P. Warde, and C. Ménard Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer Clin Cancer Res 18 2012 2108 2114
8. P.P. Peduzzi, J.J. Concato, and A.R.A. Feinstein Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates J Clin Epidemiol 48 1995 1503 1510
9. D.F. Hayes, J. Allen, and C. Compton Breaking a vicious cycle Sci Transl Med 5 2013 196cm6
10. S. Roychowdhury, and A.M. Chinnaiyan Advancing precision medicine for prostate cancer through genomics J Clin Oncol 31 2013 1866 1873
11. G. Zafarana, A.S. Ishkanian, and C.A. Malloff Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy Cancer 118 2012 4053 4062
12. J.A. Locke, G. Zafarana, and A.S. Ishkanian NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy Clin Cancer Res 18 2012 308 316
13. J.A. Locke, G. Zafarana, and C.A. Malloff Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer Prostate 72 2012 1295 1305
14. A. Dal Pra, E. Lalonde, and J. Sykes TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: Implications for fusion status and DSB repair Clin Cancer Res 19 2013 5202 5209
15. D.J. Grignon, R. Caplan, and F.H. Sarkar p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610 J Natl Cancer Inst 89 1997 158 165
16. M.A. Ritter, K.W. Gilchrist, and M. Voytovich The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer Int J Radiat Oncol Biol Phys 53 2002 574 580
17. R. Vergis, C.M. Corbishley, and K. Thomas Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation Int J Radiat Oncol Biol Phys 78 2010 35 41
18. A.A. Chakravarti, K.K. Heydon, and C.L.C. Wu Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: An analysis from the Radiation Therapy Oncology Group protocol 86-10 J Clin Oncol 21 2003 3328 3334
19. A. Bylund, P. Stattin, and A. Widmark Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy Radiother Oncol 49 1998 143 148
20. A. Pollack, D. Cowen, and P. Troncoso Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x Cancer 97 2003 1630 1638
21. L.-Y. Khor, M. DeSilvio, and R. Li Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10 Int J Radiat Oncol Biol Phys 66 2006 25 30
22. M. Abdel-Wahab, B.A. Berkey, and A. Krishan Influence of number of CAG repeats on local control in the RTOG 86-10 protocol Am J Clin Oncol 29 2006 14 20
23. J.F. Torres-Roca, M. DeSilvio, and L.B. Mora Activated STAT3 as a correlate of distant metastasis in prostate cancer: A secondary analysis of Radiation Therapy Oncology Group 86-10 Urology 69 2007 505 509
24. L.-Y. Khor, K. Bae, and T. Al-Saleem Protein Kinase A RI-α predicts for prostate cancer outcome: Analysis of Radiation Therapy Oncology Group Trial 86-10 Int J Radiat Oncol Biol Phys 71 2008 1309 1315
25. P. Bouchaert, S. Guerif, and C. Debiais DNA-PKcs expression predicts response to radiotherapy in prostate cancer Int J Radiat Oncol Biol Phys 84 2012 1179 1185